Skip to main content Skip to search Skip to main navigation

ICH: Parallel Guidances Q2(R2)/Q14 on Analytical Procedures adopted

The Assembly of the International Council for Harmonisation (ICH) adopted the revised Q2(R2) Guideline on the Validation of Analytical Procedures and the new Q14 Guideline on Analytical Procedure Development. They jointly describe the development and validation activities that should be applied during the life cycle of an analytical procedure to assess the quality of medicinal substances and products.

Both documents reached Step 4 of the ICH process, are now harmonised, and represent the current state of science and technology. This was announced following the ICH's 31 October 2023 meeting in Prague. Draft documents for the guidelines were first presented in March 2022 (we reported).

  • The scope of the revision of ICH Q2(R1) includes validation principles that cover the analytical use of spectroscopic or spectrometry data (e.g., NIR, Raman, NMR, or MS) some of which often require multivariate statistical analyses.
  • The new guideline Q14 provides principles relating to the description of the analytical procedure development process. It is intended to improve regulatory communication between industry and regulators and facilitate more efficient, sound scientific, and risk-based approval as well as post-approval change management of analytical procedures.

An Expert Working Group (EWG) will now transition to an Implementation Working Group (IWG) to develop training materials for both guidelines. Furthermore, the guidelines will be implemented and published shortly on the ICH website. This step is currently pending. The Q2(R2) and Q14 guidelines are intended to complement the ICH guidelines Q8 to Q12, as well as the current ICH guideline Q13 for continuous manufacturing.


Source:

ICH: Press Release on ICH Assembly Meeting, Prague, Oct 2023

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
EU: Proposal for a European Biotech Act

EU: Proposal for a European Biotech Act

The European Commission has presented a proposal for a European Biotech Act aimed at strengthening Europe’s biotechnology potential and accelerating the translation of innovation from the laboratory to the market.

Read more
EU: Proposal for Simplification of Medical Device Rules

EU: Proposal for Simplification of Medical Device Rules

The European Commission has proposed targeted reforms to simplify the Medical Device Regulation (Regulation (EU) 2017/745, MDR) and the In Vitro Diagnostic Regulation (Regulation (EU) 2017/746, IVDR) and to address structural implementation challenges.
Read more
EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

The EMA has published a concept paper outlining a future revision of Annex 3 (Manufacture of Radiopharmaceuticals) of the EU GMP Guidelines. The paper was developed in collaboration with PIC/S and adopted by the GMDP Inspectors Working Group (IWG) at its November meeting.

Read more
EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
Previous
Next